LF Maxfield

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background Replication-incompetent adenovirus vectors have shown promise as vaccine candidates. We are developing replication-competent adenovirus vectors to increase antigen expression and duration and to facilitate mucosal routes of vaccine delivery. We have developed replication-competent Ad5 (rcAd5) and Ad26 (rcAd26) based vectors, tested their growth(More)
Background In the phase IIb Step study, vaccinees with baseline Ad5specific neutralizing antibodies (NAbs) exhibited a potential increased rate of HIV-1 acquisition as compared with placebo controls. We sought to evaluate whether baseline Ad5 NAbs correlated with NAbs to non-type C rare Ad serotypes and whether baseline NAbs to rare Ad serotypes correlated(More)
Background The immunogenicity of adenovirus serotype 5 (Ad5) vectors is suppressed by pre-existing neutralizing antibodies (NAbs) that are directed primarily against the hexon hypervariable regions (HVRs). We previously reported that replacing all 7 HVRs of the Ad5 hexon protein with those from the rare serotype Ad48 resulted in a chimeric Ad5HVR48(1–7)(More)
  • 1